Consolidated Financial Results
For the Consolidated Fiscal Year Ended March 31, 2024

from the beginning

Consolidated Financial Results For the Consolidated Fiscal Year Ended March 31, 2024

• Net income & ROE

• Breakdown of Segment Profits

• Segment Profits

• Segment Assets

• FY24.3 Results

• FY25.3 Forecast

• Reference: Final Year of Medium-term Outlook

• Operating Climate: FY25.3 Direction

• Shareholder Returns: Hiking Dividend Payout Ratio

• Credit Ratings

• Capital Allocation: ROA, ROE & ROTE

• Improving Share Price Valuation (Corporate Value): After Reaching P/B 1.0x

• Three Portfolio Categories: Finance, Operation, Investments

• FY25.3 Forecas: Three Categories

• Assets and ROA: Three Categories

• Capital Gains: Pipeline

• Purpose and Culture

Segment Information

• Corporate Financial Services and Maintenance Leasing

• Corporate Financial Services and Maintenance Leasing-About the Business

• Real Estate

• Real Estate-About the Business

• PE Investment and Concession

• PE Investment and Concession-About the Business

• Environment and Energy

• Global Renewable Energy Portfolio

• Insurance

• Life Insurance-About the Business

• Banking and Credit

• Banking About the Business

• Aircraft and Ships

• Aircraft and Ships-About the Business

• ORIX USA

• ORIX USA-About the Business

• ORIX Europe

• ORIX Europe-About the Business

• Asia and Australia

• Asia and Australia-About the Business

Appendices

• ORIX by the Numbers

• About ORIX Expertise in Business and Collective Capabilities of the Group

• About ORIX Proven Track Record of Profitability

• Capital Recycling-Profit Growth

• Capital Recycling: Large Transactions in FY24.3

• Investment Gains and Major Breakdown

• Investment Pipeline: FY25.3 and Beyond

• Growth Driver: Shift to Asset Manager Model

• ORIX Group-Asset Management Business

• Growth Driver: Inbound Tourism

• Financials Funding Structure / Employed Capital Ratio

• Financials Funding Structure

• ESG

• Disclaimer

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6